We observed a substantial number of new obesity diagnoses occurring within 7 to 14 days following the index date, which likely reflect post-hoc coding decisions made after the initiation of therapy—particularly given the regulatory approval of GLP-1 receptor agonists for obesity management. This evidence concerns the gene GLP1R and obesity disorder.